GHENT, Belgium, 12 August 2016 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Adrianus van Herk and Van Herk Investments B.V.
Van Herk Investments B.V. notified Ablynx that they have crossed the 5% threshold on 9 August 2016 as a result of the acquisition of Ablynx shares, including 1,835,276 Ablynx shares previously held by Adrianus van Herk. As a result of the transactions, Adrianus van Herk no longer holds Ablynx shares with Van Herk Investments B.V. now holding 3,290,357 Ablynx shares. The latter representing a 5.40% of the current 60,910,744 outstanding Ablynx shares.
Van Herk Investments B.V. is controlled by Adrianus van Herk in accordance with Articles 5 and 7 of the Dutch Companies Code.
Full versions of all transparency notifications are available on Ablynx website, under the section Investors (http://www.ablynx.com/investors/share-information/major-shareholders/).
Ablynx (http://www.ablynx.com/) is a biopharmaceutical company engaged in the development of Nanobodies® (http://www.ablynx.com/technology-innovation/understanding-nanobodies/), proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 40 proprietary and partnered programmes (http://www.ablynx.com/rd-portfolio/overview/) in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com (http://www.ablynx.com).
For more information, please contact
Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: email@example.com (mailto:firstname.lastname@example.org)
Director IR & Corporate Communications
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: email@example.com (mailto:firstname.lastname@example.org%20)
Follow us on Twitter @AblynxABLX
Ablynx media/analyst relations
Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss
t: +44 20 3727 1000
e: email@example.com (mailto:firstname.lastname@example.org)
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire